Endocrine Abstracts

We analyzed the results of a survey of 51 patients aged 18 to 25 years who were not exposed to 131I. Patients included in the study had a the first time nodular goiter. The median age of the patient at the time of the diagnosis of nodular goiter was 22.00 (20.32; 23.21) years. Male/female ratio was 1/16. In 23.5% of patients the site was formed against the background of autoimmune thyroiditis, in 76.5% the true nodal formations were...

Local regulation of T3 action in bone and cartilage is a novel mechanism underlying the pathogenesis of osteoarthritis (OA). Accelerated chondrocyte differentiation is a hallmark of OA and T3 regulates this process. The type 1 and 2 deiodinases (D1, D2) convert the pro-hormone T4 to the active hormone T3 whilst D3 inactivates both T3 and T4. D1 contributes to circulating T3 levels and local T3</s...

Although the physico-chemical properties of colloid are not usually considered among the factors regulating thyroid function, it is conceivable that decreasing the viscosity of the intrafollicular colloid may facilitate diffusion of thyroglobulin (Tg) molecules within the lumina. The resulting increase in the number of contacts between Tg molecules and peroxidase at the apical membrane may promote the coupling reaction. Rats on a hormonal diet were given 0.5 μg T4</s...

Annexin 1 (ANXA1) is a member of the annexin family of phospholipid- and calcium- binding proteins with a well-demonstrated role in the inhibitory actions of glucocorticoids on the release of ACTH, TSH, GH and PRL from the anterior pituitary. ANXA1 and ANXA1 truncated peptides have also recently been found to mimic glucocorticoid suppression of LH release (John et al, 2003 J Neuroendocrinol 15, 946-57). Here we test the hypothesis that because ANXA1 mediates some of the inhibi...

It has been noted that there are differences in the hypothalamic-pituitary-adrenal (HPA) axis between the sexes, as well as changes in the axis with age. The differences in the HPA axis between the gender and age groups are thought to be due to differences in the efficiency of glucocorticoid (GC) negative feedback. The pituitary, a principle site of GC negative feedback, is the focus of this investigation. Annexin-1 (ANXA1) is a member of the annexin family of phospholipid- an...

Herein, we present the case of a 48yo Caucasian male diagnosed with a well differentiated (WD) pancreatic NET. At primary resection in 2014 pathological staging was pT3N1M0 R0 with Ki67 4%. 5 years later he developed recurrence in local lymph nodes and started on lanreotide followed by IRE on subsequent progression. In 2020, there was strongly DPET-avid metastases in mesenteric nodes and liver, so he was enrolled onto the COMPETE trial1. There was sequential progressive diseas...

In ovine placenta, binucleate cells (BNCs) are formed from trophectodermal uninucleate cells and produce placental lactogen (PL) and pregnancy associated glycoproteins (PAGs). BNC numbers cells are stable throughout most of pregnancy, yet fall abruptly just before term (Wooding et al., 1994), at a time when endogenous fetal cortisol levels are rising. This study looked at the effect of abolishing the normal prepartum cortisol rise by fetal adrenalectomy on the BNC population i...

The Metabolic Syndrome (insulin resistance, hyperglycaemia, dyslipidaemia, hypertension) amplified by visceral obesity resembles Cushing's but plasma cortisol levels are not usually elevated. To explain this paradox altered tissue sensitivity to glucocorticoids has been invoked. 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) reactivates cortisone to cortisol, thus amplifying local glucocorticoid action. An adipose-selective increase in 11b-HSD1 may underlie the Metabolic S...

Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...

PARADIGHM is an actively recruiting, prospective, observational registry (NCT01922440/EUPAS16927). The primary objective is to evaluate the safety and effectiveness of recombinant human parathyroid hormone, rhPTH(1-84), treatment in patients with chronic hypoparathyroidism under routine clinical care. The secondary objective is tocharacterize the clinical course of chronic hypoparathyroidism under conditions of routine clinical practice. At enrollment, registry inclusion crite...